Abstract
Rationale Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Identifying patients early may allow intervention which could limit progression. The ‘indeterminate for UIP’ (iUIP) CT pattern, defined in the 2018 IPF guidelines, could be a precursor to IPF but there is limited data on how patients with iUIP progress over time.
Objective To evaluate the radiological progression of iUIP and explore factors linked to progression to IPF.
Methods We performed a retrospective analysis of a lung fibrosis clinic cohort (n=230) seen between 2013-2017. Cases with iUIP were identified; first ever CTs for each patient found and categorised as ‘non-progressor’ or ‘progressors’ (the latter defined as increase in extent of disease or to ‘definite’ or ‘probable’ UIP CT pattern) during their follow up. Lung function trends, haematological data and patient demographics were examined to explore disease evolution and potential contribution to progression.
Results 48 cases with iUIP CT pattern were identified. Of these, 32 had follow up CT scans, of which 23 demonstrated progression. 17 patients in this cohort were diagnosed with IPF over a mean (S.D.) period of 3.9 (±1.9) years. Monocyte [HR 23, CI 1.6-340, p=0.03] and neutrophil levels [HR 1.8, CI 1.3-2.3, p<0.001] obtained around the time of initial CT, were associated with progression to IPF using Cox proportional hazard modelling.
Conclusion 53% of our evaluable iUIP patients progressed to IPF over a mean of four years. Monocyte and neutrophil levels at initial CT were significantly associated with progression in disease. These data provide a single-centre analysis of the evolution of patients with iUIP CT pattern, and first signal for potential factors associated with progression to IPF.
What is the key question?How does the ‘indeterminate for UIP’ (iUIP) interstitial CT pattern evolve over time and what factors are associated with progression to definite and probable UIP pattern.
What is the bottom line?In this retrospective single centre analysis, 53% of evaluable cases with iUIP on initial CT scan progressed to probable or definite UIP CT pattern over an average of 4 years. Monocyte and neutrophil levels performed around the time of initial CT were significantly associated with progression to definite and probable UIP pattern.
Why read on?We discuss the implications of these findings, its strengths and limitations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval The study was part of a study to examine the factors associated with disease progression in IPF (ethical approval 14/SC/1060 from the Health Research authority and South-Central National Research Ethics Service).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.